1. Home
  2. Products
  3. Doptelet® (avatrombopag)
  4. Efficacy
  5. Effectiveness following switch from other TPO-RA
Doptelet

Effectiveness following switch from other TPO-RA

A retrospective, observational study included both primary (25/44) and secondary (19/44) ITP patients. The results presented only refer to those patients with primary ITP from supplementary data.1  23% of patients switched from eltrombopag to Doptelet and 75% switched from romiplostim. One patient had previous experience with both eltrombopag and romiplostim.1 

Switching to Doptelet produced an effective response1,2

Patients who do not have an adequate response to their TPO-RA treatment may benefit from switching to a different TPO-RA, as recommended by ICR guidelines.1,3

Graph

Switching to Doptelet reduced the need for concomitant steroids1

In a retrospective, observational study, 43% (19/44) of patients were receiving concomitant corticosteroids before switching to Doptelet. For primary patients, the figure is 40% (10/25).1

Doptelet avatrombopag tablets

Doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).2

ICR, international consensus report; ITP, immune thrombocytopenia; TPO-RA, thrombopoietin receptor agonist.

References

1. Al-Samkari H et al. Br J Haematol. 2022; 197(3):359–366. 2. Doptelet EMC Summary of Product Characteristics. Available at: www.medicines.org.uk/emc/product/11837/smpc#gref Last accessed: April 2025. 3. ​​​​​Provan D et al. Blood Adv. 2019; 3(22):3780–3817.

 

Doptelet is a registered trademark of AkaRx, Inc., a Sobi company. Sobi is a trademark of Swedish Orphan Biovitrum AB (publ) © 2025 Sobi, Inc. – All rights reserved.

Adverse events should be reported. Reporting forms and information can be found at
www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App
Store (for United Kingdom) and www.hpra.ie (for Republic of Ireland). Adverse events should also be reported to Swedish Orphan Biovitrum Ltd at [email protected] or Telephone +44 (0) 800 111 4754

PP-18708
Other sites
expand_less